This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Terbinafine is an antifungal medication that the Food and Drug Administration (FDA) approved on March 9, 1999, for use as a topical cream. Later, an oral form of terbinafine was approved on September 28, 2007. It is used to treat fungal infections of the skin and nails, such as athlete's foot, ringworm, and toenail fungus.
Mechanism of Action of undefined
Terbinafine works by inhibiting squalene epoxidase, an enzyme essential for the synthesis of ergosterol, a vital component of fungal cell membranes. By blocking this enzyme, terbinafine disrupts the integrity of the fungal cell membrane, leading to cell death. It has a broad spectrum of activity against dermatophytes, moulds, and yeasts, making it effective in treating a wide variety of fungal infections.
Uses of undefined
Terbinafine is an antifungal medication primarily used to treat dermatophyte infections, such as tinea corporis, tinea cruris, tinea pedis, and onychomycosis. It is effective in treating superficial fungal infections of the skin, nails, and hair by targeting the underlying fungal cause. Additionally, terbinafine is utilised for the treatment of onychomycosis, a fungal nail infection that is notoriously difficult to treat. It also serves as an alternative treatment for dermatophyte-induced infections in immunocompromised patients, offering relief when other therapies fail.
undefined Drug administaration and Dosage available
Take terbinafine with or without food. If taking the oral form, swallow the tablet whole with a glass of water. Avoid crushing, chewing, or breaking the tablet. Adhere to the prescribed dosage and duration of treatment. For onychomycosis, therapy may last several months due to slow nail regrowth.
Warnings, Precautions and Side Effects of undefined
Warnings
- Serious Reactions: Terbinafine may cause severe liver damage, which can be life-threatening. It should be discontinued immediately if signs of liver problems, such as jaundice, dark urine, or persistent abdominal pain, occur.
- Monitoring: Regular liver function tests are recommended before starting therapy and during treatment, particularly for those with pre-existing liver conditions.
- Hepatic Risk: Terbinafine is contraindicated in patients with chronic or active liver disease. In such cases, close monitoring or an alternative therapy should be considered.
- Allergic Reactions: Discontinue use if serious allergic reactions, such as rash, itching, or difficulty breathing, occur.
Precautions
Patients with impaired liver function should use terbinafine cautiously, as it can worsen liver damage. Those with renal impairment should also exercise caution and regularly monitor kidney function during treatment. Although terbinafine is classified as a Category B medication for pregnancy and is generally considered safe, it should still be used with caution. Pregnant women or those planning to become pregnant should consult a doctor before using it. Elderly patients may require dosage adjustments, especially if they have underlying renal or hepatic dysfunction.
Side Effects
Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.
Common side effects of Terbinafine:
- Gastrointestinal discomfort (nausea, dyspepsia)
- Headache
- Skin rash
- Diarrhea
- Altered taste sensation (dysgeusia)
Serious side effects of Terbinafine:
- Hepatotoxicity (liver damage)
- Severe allergic reactions (urticaria, angioedema)
- Acute generalised exanthematous pustulosis
- Neutropenia (low white blood cell count)
- Persistent or unexplained gastrointestinal symptoms
- Yellowing of the skin or eyes (jaundice)
- Renal dysfunction (rare)
Word Of Advice
When prescribed terbinafine, monitor for signs of liver dysfunction such as jaundice, dark urine, or abdominal pain. Contact your healthcare provider immediately if any severe side effects occur. Adhere to your prescribed treatment regimen, and avoid stopping or altering the dosage without consulting your doctor. Regular blood tests, including liver function tests, may be required. If you experience any signs of an allergic reaction or unusual symptoms, inform your healthcare provider promptly.
Frequently Asked Question
References
1. Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B. Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis. https://pmc.ncbi.nlm.nih.gov/articles/PMC5527721/
2. Newland JG, Abdel-Rahman SM. Update on terbinafine with a focus on dermatophytoses. https://pmc.ncbi.nlm.nih.gov/articles/PMC3047923/
3. van der Schroeff JG, Cirkel PK, Crijns MB, Van Dijk TJ, Govaert FJ, Groeneweg DA, Tazelaar DJ, De Wit RF, Wuite J. A randomized treatment duration-finding study of terbinafine in onychomycosis. https://pubmed.ncbi.nlm.nih.gov/1531927/
Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare provider for specific guidance on diagnosis and treatment.